Meeting
2019 ASCO Annual Meeting
Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
Authors
Naomi RM Schwartz
University of Washington, Seattle, WA
Naomi RM Schwartz , Meghan Rose Flanagan , Joseph B Babigumira , Lotte Maria Gertruda Steuten , Joshua A. Roth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6625)
DOI
10.1200/JCO.2019.37.15_suppl.6625
Abstract #
6625
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2015 Breast Cancer Symposium
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.
First Author: Arlene Chan
Poster
2021 ASCO Annual Meeting
Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.
First Author: Gavin M. Marx
Poster
2019 ASCO Annual Meeting
Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.
First Author: Carlos Hernando Barcenas
Poster
2018 ASCO Annual Meeting
Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early‑stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.
First Author: Bent Ejlertsen